Chiltern announces it was selected as the partner CRO for Karolinska Development
Chiltern announces it was selected as the partner CRO for Karolinska Development, a publicly-traded life sciences investment company that brings selects and develops the most commercially attractive medical innovations to the point of sales or out-licensing to other companies. The extensive CRO selection process began in 2012 and the company states it was selected based on its compatibility with Karolinska's needs for global infrastructure, and approach to deliver on innovation, quality and flexibility.
